Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CD4-IgG

Phase 1Small molecule

CD4-IgG is one of 98 small molecule programs targeting HIV infection. It is currently in Phase 1.

3

Indications

6

Total Trials

0

Active Trials

97

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

Thrombocytopenic PurpuraActive, not recruiting

HIV-1 InfectionActive, not recruiting

HIV InfectionPreclinical

Active, not recruiting

Thrombocytopenic PurpuraPhase 1

Active, not recruiting

HIV-1 InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

326 competitors in HIV Infection

#DrugCompanyPhaseTrials

Leukine

Betaseron

PEG-Intron

Megace

Bristol-Myers Squibb

Proleukin

IIovance Biotherapeutics, Inc.

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

TWINRIX™

F/TAF

F/TDF

PTM SEMA

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intravenous2 trials

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000675·60 enrolled

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000976·40 enrolled

Pregnancy1 trial

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000642·30 enrolled

HIV infection1 trial

An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000647·6 enrolled

HIV-1 infection1 trial

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000663·18 enrolled

Thrombocytopenic Purpura1 trial

A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura

Completed· Roche logo

Roche·Phase 1·NCT00002250

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for CD4-IgG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD4-IgG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD4-IgG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

Related News